# A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

> **NCT06508021** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ashibio Inc** · enrollment: 92 (estimated)

## Conditions studied

- Fibrodysplasia Ossificans Progressiva

## Interventions

- **DRUG:** Andecaliximab
- **DRUG:** Placebo
- **DRUG:** Andecaliximab

## Key facts

- **NCT ID:** NCT06508021
- **Lead sponsor:** Ashibio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-25
- **Primary completion:** 2029-02-04
- **Final completion:** 2029-02-04
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508021, "A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06508021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*